Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

Roche (RHHBY) presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting. CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity. However, shares of the company were down 6% on Sept. 11, post the presentation on concerns of side-effects from the investigational obesity drug. Image Source: Zacks Investment Research Ye ...